ScaI Atrial Natriuretic Peptide Gene Polymorphism and Hypertension in the Tunisian Population
Keywords:
Atrial natriuretic peptide, ANP polymorphism, ANP/T2233C gene polymorphism, hypertensionAbstract
Numerous genetic variants have been linked to hypertension. Among these variants T2238C polymorphism in atrial natriuretic peptide gene has been investigated in the pathogeneses of hypertension, but studies have often generated controversial results. The aim of this study was to investigate the association between hypertension and the ANP/ T2238C variant gene that led to the loss of ScaI restriction site, thus eliminated the regular stop codon and involved an extension of the human ANP by two additional arginines. We genotyped 384 patients with hypertension and 435 healthy controls. The ScaI ANP gene polymorphism was determined by polymerase chain reaction-restriction fragment length polymorphism analysis. The results shows that the ScaI ANP gene polymorphism genotypes distribution and allele frequencies were not significantly different between the hypertensive and normotensive subjects (p>0.05). The frequencies of A2 wild allele and A1 mutant allele were 48% and 52% respectively in hypertensive patients and 49% and 51% in control group (p=0.66). This polymorphism is not associated with hypertension (OR= 1.55, 95% CI [0.82-2.92]; p=0.17) for TC and (OR=1.80, 95% CI [0.81-3.98]; p=0.14) for CC after adjustment for age, gender, body mass index, fasting glucose concentration, dyslipidemia and smoking. Furthermore, no relationship was found between clinical characteristics and ScaI ANP genotypes. As a conclusion; this study suggested that the ScaI ANP gene polymorphism is not associated with hypertension in the Tunisian population.
References
Ward R (1990): Familial aggregation and genetic epidemiology of blood pressure, in Hypertension: Pathophysiology, Diagnosis, and Management,Laragh, JH and Brenner BM, editors,Raven Press, New York; 81-100.
De Bold AJ, Borenstein HB, Veress AT, Sonnenberg H (1981): A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. LifeSci; 28:89-94.
Levin ER, Gardner DG, Samson WK (1998):Natriuretic peptides. N EnglJ Med;339:321-8.
Masharani U, Nakashima P, Lim DW, Frossard PM, Nsi I (1988):Sca I restriction fragment length polyporphisms at the atrial natriuretic peptides (ANP) gene locus. Hum Genet; 80:307.
Ramasawmy R, Kotea N, Lu C, Sayada C, Baligadoo S, Krishnamoorthy R (1992):Investigation of the polymorphic Sca I site by a PCR-based assay at the human atrial natriuretic peptide (hANP) gene locus. Hum Genet. 90:323-4.
Rutledge DR, Sun Y, Ross FA (1995): Polymorphisms within the atrial natriuretic peptide gene in essential hypertension. J Hypertens;13:953-5.
Schorr U, Beige J, Ringel J,Turan S, Kreutz R, Distler A et al.(1997): HpaII polymorphism of the atrial natriuretic peptide gene and the blood pressure response to salt intake in normotensive men. J Hypertens; 15:715-8.
Rabattu S, Stanzione R, Angelantonio ED, Zanda B, Evangelista A, Tarasi D et al.(2004): Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke 35: 814-8.
Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A et al. (2009): Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet ;41 : 348
Kato N, Sugiyama T, Murita H, Nabika T, Kurihara H, Yamori T et al.(2000): Genetic analysis of the atrial natriuretic peptide gene in essential hypertension. ClinSci; 98: 251
Beige J, Ringel J, Hohenbleicher H, Rubattu S, KreutzR, Sharma AM (1997):HpaII polymorphism of the atrial natriuretic peptide gene and essential hypertension in whites. Am J Hypertens; 10: 1316
Xue H, Wang S, Wang H, Sun K, Song Y, Zhang W et al. (2008): Atrial natriuretic peptide gene promoterpolymorphism is associated with left ventricularhypertrophy in hypertension ClinSci (Lond); 114: 131
Rahmutula D, Nakayama T, Soma M, Takahashi Y, Kunimoto M, Uwabo J et al.(2001):Association study between the variants of the human ANP gene and essential hypertension. Hypertens Res; 24: 291-4.
Nkeh B, Tiago A, CandyG, Woodiwiss AJ, Badenhorst D, Luker F.et al. (2002): Association between an atrial natriuretic peptide gene polymorphism and normal blood pressure in subjects of african ancestry. Cardiovasc J South Afr; 13:97-101.
Conen D, Glynn RJ,Buring JE, Ridker PM, ZeeRYL (2007): Natriuretic Peptide Precursor A Gene Polymorphismsand Risk of Blood Pressure Progression andIncident Hypertension.Hypertens;50:1114-1119.
Larifla L, Maimaintiming S, Velayoudom-Cephise FL, Ferdinand S, Deverly AB, Ben Abdallah S et al. (2012): Association of 2238T/C polymorphism of the atrial natriuretic peptide gene with coronay artery disease in Afro-Caribbens with type 2 diabetes. Am J Hypertens; 25:524-7
World Health Organisation (1999): International society of Hypertension Guide-line for the Management of hypertension. J Hypertens; 17:151-83.
World Health Organization (1995): Physical status: the use and interpretation anthropometry: Report of a WHO expert committee, WHO Technical Report Series, no. 854. Geneva: WHO; p. 321-44.
National Institutes of Health National Heart Lung and Blood Institute Obesity. Education Initiative (1998): Expert panel on the identification, evaluation, and treatment of overweight and obesity in adults; 98-4083:1-226.
Marcadet A, O
Gauderman WJ, Morrison JM (2006): QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies. http://hydra.usc.edu/gxe.
Rabattu S, Bigatti G, Evangelista A, Evangelista A, Lanzani C, Stanzione Ret al. (2006): Association of atrial natriuretic peptide and type A natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am CollCardiol; 48:499-505.
Rubattu S, Evangelista A, Barbato D, Barba G, Stanzione R, Iacone R et al. (2007): Atrial natriuretic peptide (ANP) gene promoter variant and increased susceptibility to early development of hypertension in humans.J Hum Hypertens; 21, 822
Nakayama T, Soma M, Takahashi Y, Rehemudula D, Danmatsuse K, Furuya K (2000): Functional deletion mutation of the 5
Mannipieri M, Manganiello M, Pezzartini A, De Bellis A, Seghieri G, Ferranini E (2001): Polymorphisms in the h ANP (human atrial natriuretic peptide) gene, albuminuria, and hypertension. Hypertens; 37:1416-22.
Nannipieri M, Posadas R, Williams K, Politi E, Gonzales-Villalpando C, Stern MPet al. (2003): Association between polymorphisms of the atrial natriuretic peptide gene and proteinuria: a population-based study. Diabetologia; 46:429-32.
Kato N, Sugiyama T, Morita H, Nabika T, Kurihara H, Yamori Yet al.(2000): Genetic analysis of the atrial natriuretic peptide gene in essential hypertensio. ClinSci (Lond); 98: 251-8.
Cheung BMY, Leung R, Shiu S, Tang KCB, Lau CP, Kumana CR (1999):Hpa II polymorphism in the atrial natriuretic peptide gene and hypertension. Am J Hypertens; 12:524-7.
De Bold AJ, Ma KK, Zhang Y, De Bold ML, Bensimon M, Khoshbaten A (2001): The physiological and pathophysiological modulation of the endocrine function of the heart. Can J PhysiolPharmacol; 79: 705-14.
Pankaj A, Connie W, Abigail MK, Donald BB, Brandi NDD, Anahita G et al. (2013): Atrial natriuretic peptide is negativelyregulated by microRNA-425. J Clin Invest; 123: 3378-82.
Downloads
Published
How to Cite
Issue
Section
License
Authors who submit papers with this journal agree to the following terms.
